Castle Biosciences, Inc.
CSTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $332,069 | $219,788 | $137,039 | $94,085 |
| % Growth | 51.1% | 60.4% | 45.7% | – |
| Cost of Goods Sold | $60,205 | $44,982 | $32,009 | $15,822 |
| Gross Profit | $271,864 | $174,806 | $105,030 | $78,263 |
| % Margin | 81.9% | 79.5% | 76.6% | 83.2% |
| R&D Expenses | $52,041 | $53,618 | $44,903 | $29,646 |
| G&A Expenses | $76,580 | $66,495 | $56,396 | $0 |
| SG&A Expenses | $200,047 | $180,152 | $143,003 | $86,738 |
| Sales & Mktg Exp. | $123,467 | $113,657 | $86,607 | $0 |
| Other Operating Expenses | $11,106 | $9,013 | -$10,021 | $1,958 |
| Operating Expenses | $263,194 | $242,783 | $177,885 | $118,342 |
| Operating Income | $8,670 | -$67,977 | -$72,855 | -$40,079 |
| % Margin | 2.6% | -30.9% | -53.2% | -42.6% |
| Other Income/Exp. Net | $12,894 | $10,612 | $3,951 | $67 |
| Pre-Tax Income | $21,564 | -$57,365 | -$68,904 | -$40,012 |
| Tax Expense | $3,319 | $101 | -$1,766 | -$8,720 |
| Net Income | $18,245 | -$57,466 | -$67,138 | -$31,292 |
| % Margin | 5.5% | -26.1% | -49% | -33.3% |
| EPS | 0.66 | -2.14 | -2.58 | -1.24 |
| % Growth | 130.8% | 17.1% | -108.1% | – |
| EPS Diluted | 0.62 | -2.14 | -2.58 | -1.24 |
| Weighted Avg Shares Out | 27,776 | 26,802 | 26,054 | 25,137 |
| Weighted Avg Shares Out Dil | 29,255 | 26,802 | 26,054 | 25,137 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12,916 | $10,623 | $3,968 | $68 |
| Interest Expense | $577 | $11 | $17 | $1 |
| Depreciation & Amortization | $15,997 | $12,330 | $10,543 | $3,407 |
| EBITDA | $38,138 | -$45,024 | -$58,344 | -$36,604 |
| % Margin | 11.5% | -20.5% | -42.6% | -38.9% |